

# Neurofibromatosis 2 Market Insights, Epidemiology and Market Forecast- 2028

<https://marketpublishers.com/r/NED62711825EN.html>

Date: April 2019

Pages: 120

Price: US\$ 6,250.00 (Single User License)

ID: NED62711825EN

## Abstracts

This report can be delivered to the clients within 7-10 business days

DelveInsight's "Neurofibromatosis 2 - Market Insights, Epidemiology and Market Forecast – 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028.

### Markets Covered

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2017-2028

### Neurofibromatosis 2 Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Neurofibromatosis 2 in the US, Europe, and Japan are also provided in

the report.

## Neurofibromatosis 2 Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

## Neurofibromatosis 2 Product Profiles & Analysis

This part of the Neurofibromatosis 2 report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

## Neurofibromatosis 2 Market Outlook

The Neurofibromatosis 2 market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

## Neurofibromatosis 2 Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

## Neurofibromatosis 2 Report Insights

Patient Population in Neurofibromatosis 2

Therapeutic Approaches in Neurofibromatosis 2

Neurofibromatosis 2 Pipeline Analysis

Neurofibromatosis 2 Market Size and Trends

Neurofibromatosis 2 Market Opportunities

Impact of upcoming Therapies in Neurofibromatosis 2

## Neurofibromatosis 2 Report Key Strengths

10 Year Forecast

7MM Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

## Neurofibromatosis 2 Report Assessment

Current Treatment Practices in Neurofibromatosis 2

Unmet Needs in Neurofibromatosis 2

Detailed Neurofibromatosis 2 Pipeline Product Profiles

Market Attractiveness

Market Drivers and Barriers

### Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Neurofibromatosis 2 market

Organize sales and marketing efforts by identifying the best opportunities for Neurofibromatosis 2 market

To understand the future market competition in the Neurofibromatosis 2 market.

Note: We understand the needs of the rapidly changing market and DelveInsight's is helping the client by providing the most up to date Report. It usually takes 7-10 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

## Contents

### **1. REPORT INTRODUCTION**

### **2. NEUROFIBROMATOSIS 2 MARKET OVERVIEW AT A GLANCE**

2.1. Market Share Distribution of Neurofibromatosis 2 in 2018

2.2. Market Share Distribution of Neurofibromatosis 2 in 2028

### **3. DISEASE BACKGROUND AND OVERVIEW: NEUROFIBROMATOSIS**

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

### **4. EPIDEMIOLOGY AND PATIENT POPULATION**

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Neurofibromatosis 2 in 7MM

4.3. Total Prevalent Patient Population of Neurofibromatosis 2 in 7MM – By Countries

### **5. EPIDEMIOLOGY OF NEUROFIBROMATOSIS 2 BY COUNTRIES**

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Neurofibromatosis

5.1.3. Sub-Type Specific cases of the Neurofibromatosis 2 \*Indication Specific

5.1.4. Sex- Specific Cases of the Neurofibromatosis 2\*Indication Specific

5.1.5. Diagnosed Cases of the Neurofibromatosis

5.1.6. Treatable Cases of the Neurofibromatosis

5.2. EU5

5.3. Assumptions and Rationale

5.4. Germany

5.4.1. Assumptions and Rationale

5.4.2. Prevalent/Incident Cases of the Neurofibromatosis

5.4.3. Sub-Type Specific cases of the Neurofibromatosis 2\*

- 5.4.4. Sex- Specific Cases of the Neurofibromatosis 2\*
- 5.4.5. Diagnosed Cases of the Neurofibromatosis
- 5.4.6. Treatable Cases of the Neurofibromatosis
- 5.5. France
  - 5.5.1. Assumptions and Rationale
  - 5.5.2. Prevalent/Incident Cases of the Neurofibromatosis
  - 5.5.3. Sub-Type Specific cases of the Neurofibromatosis 2\*
  - 5.5.4. Sex- Specific Cases of the Neurofibromatosis 2\*
  - 5.5.5. Diagnosed Cases of the Neurofibromatosis
  - 5.5.6. Treatable Cases of the Neurofibromatosis
- 5.6. Italy
  - 5.6.1. Assumptions and Rationale
  - 5.6.2. Prevalent/Incident Cases of the Neurofibromatosis
  - 5.6.3. Sub-Type Specific cases of the Neurofibromatosis 2\*
  - 5.6.4. Sex- Specific Cases of the Neurofibromatosis 2\*
  - 5.6.5. Diagnosed Cases of the Neurofibromatosis
  - 5.6.6. Treatable Cases of the Neurofibromatosis
- 5.7. Spain
  - 5.7.1. Assumptions and Rationale
  - 5.7.2. Prevalent/Incident Cases of the Neurofibromatosis
  - 5.7.3. Sub-Type Specific cases of the Neurofibromatosis 2\*
  - 5.7.4. Sex- Specific Cases of the Neurofibromatosis 2\*
  - 5.7.5. Diagnosed Cases of the Neurofibromatosis
  - 5.7.6. Treatable Cases of the Neurofibromatosis
- 5.8. United Kingdom
  - 5.8.1. Assumptions and Rationale
  - 5.8.2. Prevalent/Incident Cases of the Neurofibromatosis
  - 5.8.3. Sub-Type Specific cases of the Neurofibromatosis 2\*
  - 5.8.4. Sex- Specific Cases of the Neurofibromatosis 2\*
  - 5.8.5. Diagnosed Cases of the Neurofibromatosis
  - 5.8.6. Treatable Cases of the Neurofibromatosis
- 5.9. Japan
  - 5.9.1. Assumptions and Rationale
  - 5.9.2. Prevalent/Incident Cases of the Neurofibromatosis
  - 5.9.3. Sub-Type Specific cases of the Neurofibromatosis 2\*
  - 5.9.4. Sex- Specific Cases of the Neurofibromatosis 2\*
  - 5.9.5. Diagnosed Cases of the Neurofibromatosis
  - 5.9.6. Treatable Cases of the Neurofibromatosis

## **6. CURRENT TREATMENT & MEDICAL PRACTICES**

- 6.1. Treatment Algorithm
- 6.2. Treatment Guidelines

## **7. UNMET NEEDS OF THE NEUROFIBROMATOSIS**

## **8. MARKETED THERAPIES**

- 8.1. Drug A: Company
  - 8.1.1. Drug Description
  - 8.1.2. Mechanism of Action
  - 8.1.3. Regulatory Milestones
  - 8.1.4. Advantages & Disadvantages
  - 8.1.5. Product Profile
- 8.2. Drug B: Company
  - 8.2.1. Drug Description
  - 8.2.2. Mechanism of Action
  - 8.2.3. Regulatory Milestones
  - 8.2.4. Advantages & Disadvantages
  - 8.2.5. Product Profile

## **9. PIPELINE THERAPIES – AT A GLANCE**

## **10. KEY CROSS COMPETITION**

## **11. EMERGING THERAPIES FOR NEUROFIBROMATOSIS**

- 11.1. Drug C: Company
  - 11.1.1. Drug Description
  - 11.1.2. Clinical Trials Details
  - 11.1.3. Safety and Efficacy Profile
  - 11.1.4. Advantages & Disadvantages
  - 11.1.5. Pipeline Development Activities
  - 11.1.6. Product Profile
- 11.2. Drug D: Company
  - 11.2.1. Drug Description
  - 11.2.2. Clinical Trials Details
  - 11.2.3. Safety and Efficacy Profile
  - 11.2.4. Advantages & Disadvantages
  - 11.2.5. Pipeline Development Activities
  - 11.2.6. Product Profile

## **12. NEUROFIBROMATOSIS 2: 7MM MARKET ANALYSIS**

- 12.1. 7MM Market Size of Neurofibromatosis
- 12.2. 7MM Percentage Share of drugs marketed for Neurofibromatosis
- 12.3. 7MM Market Sales of Neurofibromatosis 2 by Products

## **13. NEUROFIBROMATOSIS 2: COUNTRY-WISE MARKET ANALYSIS**

### 13.1. United States

- 13.1.1. Market Size of Neurofibromatosis 2 in United States
- 13.1.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in United States
- 13.1.3. Market Sales of Neurofibromatosis 2 by Products in United States
- 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market

### 13.2. EU-5

#### 13.2.1. Germany

- 13.2.1.1. Market Size of Neurofibromatosis 2 in Germany
- 13.2.1.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in Germany
- 13.2.1.3. Market Sales of Neurofibromatosis 2 by Products in Germany
- 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market

#### 13.2.2. France

- 13.2.2.1. Market Size of Neurofibromatosis 2 in France
- 13.2.2.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in France
- 13.2.2.3. Market Sales of Neurofibromatosis 2 by Products in France
- 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

#### 13.2.3. Italy

- 13.2.3.1. Market Size of Neurofibromatosis 2 in Italy
- 13.2.3.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in Italy
- 13.2.3.3. Market Sales of Neurofibromatosis 2 by Products in Italy
- 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

#### 13.2.4. Spain

- 13.2.4.1. Market Size of Neurofibromatosis 2 in Spain
- 13.2.4.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in Spain
- 13.2.4.3. Market Sales of Neurofibromatosis 2 by Products in Spain
- 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

#### 13.2.5. United Kingdom

- 13.2.5.1. Market Size of Neurofibromatosis 2 in United Kingdom
- 13.2.5.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in United Kingdom



13.2.5.3. Market Sales of Neurofibromatosis 2 by Products in United Kingdom

13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

13.3. Japan

13.3.1. Market Size of Neurofibromatosis 2 in Japan

13.3.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in Japan

13.3.3. Market Sales of Neurofibromatosis 2 by Products in Japan

13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

**14. MARKET DRIVERS**

**15. MARKET BARRIERS**

**16. APPENDIX**

**17. REPORT METHODOLOGY**

17.1. Sources

**18. DELVEINSIGHT CAPABILITIES**

**19. DISCLAIMER**

**20. ABOUT DELVEINSIGHT**

## List Of Tables

### LIST OF TABLES

- Table 1: Total Prevalent/Incident Cases of the Neurofibromatosis 2 in 7MM
- Table 2: Total Prevalent/Incident Cases of the Neurofibromatosis 2 in 7MM by Countries
- Table 3: Prevalent/Incident Cases of the Neurofibromatosis 2 in United States (2017-2028)
- Table 4: Sub-Type Specific cases of the Neurofibromatosis 2 in United States (2017-2028)
- Table 5: Sex- Specific Cases of the Neurofibromatosis 2 in United States (2017-2028)
- Table 6: Diagnosed Cases of the Neurofibromatosis 2 in United States (2017-2028)
- Table 7: Treatable Cases of the Neurofibromatosis 2 in United States (2017-2028)
- Table 8: Prevalent/Incident Cases of the Neurofibromatosis 2 in Germany (2017-2028)
- Table 9: Sub-Type Specific cases of the Neurofibromatosis 2 in Germany (2017-2028)
- Table 10: Sex- Specific Cases of the Neurofibromatosis 2 in Germany (2017-2028)
- Table 11: Diagnosed Cases of the Neurofibromatosis 2 in Germany (2017-2028)
- Table 12: Treatable Cases of the Neurofibromatosis 2 in Germany (2017-2028)
- Table 13: Prevalent/Incident Cases of the Neurofibromatosis 2 in France (2017-2028)
- Table 14: Sub-Type Specific cases of the Neurofibromatosis 2 in France (2017-2028)
- Table 15: Sex- Specific Cases of the Neurofibromatosis 2 in France (2017-2028)
- Table 16: Diagnosed Cases of the Neurofibromatosis 2 in France (2017-2028)
- Table 17: Treatable Cases of the Neurofibromatosis 2 in France (2017-2028)
- Table 18: Prevalent/Incident Cases of the Neurofibromatosis 2 in Italy (2017-2028)
- Table 19: Sub-Type Specific cases of the Neurofibromatosis 2 in Italy (2017-2028)
- Table 20: Sex- Specific Cases of the Neurofibromatosis 2 in Italy (2017-2028)
- Table 21: Diagnosed Cases of the Neurofibromatosis 2 in Italy (2017-2028)
- Table 22: Treatable Cases of the Neurofibromatosis 2 in Italy (2017-2028)
- Table 23: Prevalent/Incident Cases of the Neurofibromatosis 2 in Spain (2017-2028)
- Table 24: Sub-Type Specific cases of the Neurofibromatosis 2 in Spain (2017-2028)
- Table 25: Sex- Specific Cases of the Neurofibromatosis 2 in Spain (2017-2028)
- Table 26: Diagnosed Cases of the Neurofibromatosis 2 in Spain (2017-2028)
- Table 27: Treatable Cases of the Neurofibromatosis 2 in Spain (2017-2028)
- Table 28: Prevalent/Incident Cases of the Neurofibromatosis 2 in UK (2017-2028)
- Table 29: Sub-Type Specific cases of the Neurofibromatosis 2 in UK (2017-2028)
- Table 30: Sex- Specific Cases of the Neurofibromatosis 2 in UK (2017-2028)
- Table 31: Diagnosed Cases of the Neurofibromatosis 2 in UK (2017-2028)
- Table 32: Treatable Cases of the Neurofibromatosis 2 in UK (2017-2028)
- Table 33: Prevalent/Incident Cases of the Neurofibromatosis 2 in Japan (2017-2028)

- Table 34: Sub-Type Specific cases of the Neurofibromatosis 2 in Japan (2017-2028)
- Table 35: Sex- Specific Cases of the Neurofibromatosis 2 in Japan (2017-2028)
- Table 36: Diagnosed Cases of the Neurofibromatosis 2 in Japan (2017-2028)
- Table 37: Treatable Cases of the Neurofibromatosis 2 in Japan (2017-2028)
- Table 38: Marketed Therapies
- Table 39: Emerging Therapies
- Table 40: Key Cross Competition
- Table 41:7MM- Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Table 42:7MM- Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Table 43:7MM- Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Table 44: United States-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Table 45: United States-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Table 46: United States-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Table 47: Germany-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Table 48: Germany-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Table 49: Germany-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Table 50: France-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Table 51: France-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Table 52: France-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Table 53: Italy-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Table 54: Italy-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Table 55: Italy-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Table 56: Spain-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Table 57: Spain-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Table 58: Spain-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Table 59:UK-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Table 60:UK-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Neurofibromatosis 2 by Therapies in USD MM  
(2017-2028)

Table 62: Japan-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)

Table 63: Japan-Market Share Neurofibromatosis 2 by Therapies in USD MM  
(2017-2028)

Table 64: Japan-Market Sales of Neurofibromatosis 2 by Therapies in USD MM  
(2017-2028)

## List Of Figures

### LIST OF FIGURES

- Figure 1: Total Prevalent/Incident Cases of the Neurofibromatosis 2 in 7MM
- Figure 2: Total Prevalent/Incident Cases of the Neurofibromatosis 2 in 7MM by Countries
- Figure 3: Prevalent/Incident Cases of the Neurofibromatosis 2 in United States (2017-2028)
- Figure 4: Sub-Type Specific cases of the Neurofibromatosis 2 in United States (2017-2028)
- Figure 5: Sex- Specific Cases of the Neurofibromatosis 2 in United States (2017-2028)
- Figure 6: Diagnosed Cases of the Neurofibromatosis 2 in United States (2017-2028)
- Figure 7: Treatable Cases of the Neurofibromatosis 2 in United States (2017-2028)
- Figure 8: Prevalent/Incident Cases of the Neurofibromatosis 2 in Germany (2017-2028)
- Figure 9: Sub-Type Specific cases of the Neurofibromatosis 2 in Germany (2017-2028)
- Figure 10: Sex- Specific Cases of the Neurofibromatosis 2 in Germany (2017-2028)
- Figure 11: Diagnosed Cases of the Neurofibromatosis 2 in Germany (2017-2028)
- Figure 12: Treatable Cases of the Neurofibromatosis 2 in Germany (2017-2028)
- Figure 13: Prevalent/Incident Cases of the Neurofibromatosis 2 in France (2017-2028)
- Figure 14: Sub-Type Specific cases of the Neurofibromatosis 2 in France (2017-2028)
- Figure 15: Sex- Specific Cases of the Neurofibromatosis 2 in France (2017-2028)
- Figure 16: Diagnosed Cases of the Neurofibromatosis 2 in France (2017-2028)
- Figure 17: Treatable Cases of the Neurofibromatosis 2 in France (2017-2028)
- Figure 18: Prevalent/Incident Cases of the Neurofibromatosis 2 in Italy (2017-2028)
- Figure 19: Sub-Type Specific cases of the Neurofibromatosis 2 in Italy (2017-2028)
- Figure 20: Sex- Specific Cases of the Neurofibromatosis 2 in Italy (2017-2028)
- Figure 21: Diagnosed Cases of the Neurofibromatosis 2 in Italy (2017-2028)
- Figure 22: Treatable Cases of the Neurofibromatosis 2 in Italy (2017-2028)
- Figure 23: Prevalent/Incident Cases of the Neurofibromatosis 2 in Spain (2017-2028)
- Figure 24: Sub-Type Specific cases of the Neurofibromatosis 2 in Spain (2017-2028)
- Figure 25: Sex- Specific Cases of the Neurofibromatosis 2 in Spain (2017-2028)
- Figure 26: Diagnosed Cases of the Neurofibromatosis 2 in Spain (2017-2028)
- Figure 27: Treatable Cases of the Neurofibromatosis 2 in Spain (2017-2028)
- Figure 28: Prevalent/Incident Cases of the Neurofibromatosis 2 in UK (2017-2028)
- Figure 29: Sub-Type Specific cases of the Neurofibromatosis 2 in UK (2017-2028)
- Figure 30: Sex- Specific Cases of the Neurofibromatosis 2 in UK (2017-2028)
- Figure 31: Diagnosed Cases of the Neurofibromatosis 2 in UK (2017-2028)
- Figure 32: Treatable Cases of the Neurofibromatosis 2 in UK (2017-2028)

- Figure 33: Prevalent/Incident Cases of the Neurofibromatosis 2 in Japan (2017-2028)
- Figure 34: Sub-Type Specific cases of the Neurofibromatosis 2 in Japan (2017-2028)
- Figure 35: Sex- Specific Cases of the Neurofibromatosis 2 in Japan (2017-2028)
- Figure 36: Diagnosed Cases of the Neurofibromatosis 2 in Japan (2017-2028)
- Figure 37: Treatable Cases of the Neurofibromatosis 2 in Japan (2017-2028)
- Figure 38: Marketed Therapies
- Figure 39: Emerging Therapies
- Figure 40: Key Cross Competition
- Figure 41:7MM- Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Figure 42:7MM- Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Figure 43:7MM- Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Figure 44: United States-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Figure 45: United States-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Figure 46: United States-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Figure 47: Germany-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Figure 48: Germany-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Figure 49: Germany-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Figure 50: France-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Figure 51: France-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Figure 52: France-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Figure 53: Italy-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Figure 54: Italy-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Figure 55: Italy-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Figure 56: Spain-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)
- Figure 57: Spain-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Figure 58: Spain-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)
- Figure 59:UK-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)

Figure 60:UK-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Neurofibromatosis 2 by Therapies in USD MM  
(2017-2028)

Figure 62: Japan-Market Size of Neurofibromatosis 2 in USD MM (2017-2028)

Figure 63: Japan-Market Share Neurofibromatosis 2 by Therapies in USD MM  
(2017-2028)

Figure 64: Japan-Market Sales of Neurofibromatosis 2 by Therapies in USD MM  
(2017-2028)

## I would like to order

Product name: Neurofibromatosis 2 Market Insights, Epidemiology and Market Forecast- 2028

Product link: <https://marketpublishers.com/r/NED62711825EN.html>

Price: US\$ 6,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NED62711825EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970